Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 4,693 shares of Cullinan Therapeutics stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $11.41, for a total transaction of $53,547.13. Following the completion of the transaction, the insider now directly owns 99,760 shares of the company's stock, valued at $1,138,261.60. This trade represents a 4.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Jennifer Michaelson also recently made the following trade(s):
- On Thursday, December 12th, Jennifer Michaelson sold 3,489 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.52, for a total value of $43,682.28.
- On Tuesday, November 5th, Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $15.64, for a total transaction of $125,120.00.
Cullinan Therapeutics Trading Up 5.9 %
Shares of Cullinan Therapeutics stock opened at $11.60 on Friday. The firm has a fifty day simple moving average of $14.28 and a 200-day simple moving average of $16.68. The stock has a market capitalization of $675.44 million, a price-to-earnings ratio of -4.08 and a beta of -0.18. Cullinan Therapeutics, Inc. has a 1-year low of $8.49 and a 1-year high of $30.19.
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing | Ad
Biden broke it... Now Trump is going to fix it.
Starting with "Exec. Order 001."
I put all the details together for you here — but please hurry.
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.09. As a group, research analysts predict that Cullinan Therapeutics, Inc. will post -3.12 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of CGEM. Amalgamated Bank grew its stake in shares of Cullinan Therapeutics by 97.3% in the third quarter. Amalgamated Bank now owns 1,768 shares of the company's stock worth $30,000 after acquiring an additional 872 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Cullinan Therapeutics by 73.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,883 shares of the company's stock valued at $155,000 after buying an additional 3,758 shares during the last quarter. Arizona State Retirement System bought a new stake in shares of Cullinan Therapeutics in the second quarter valued at about $182,000. Squarepoint Ops LLC acquired a new stake in Cullinan Therapeutics during the second quarter worth about $186,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Cullinan Therapeutics by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,151 shares of the company's stock valued at $187,000 after acquiring an additional 4,380 shares in the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
CGEM has been the topic of several recent research reports. HC Wainwright reissued a "buy" rating and set a $28.00 target price on shares of Cullinan Therapeutics in a research note on Wednesday, October 16th. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Cullinan Therapeutics in a research report on Wednesday, September 18th. Finally, UBS Group began coverage on Cullinan Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $30.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $31.67.
Read Our Latest Report on CGEM
Cullinan Therapeutics Company Profile
(
Get Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
